AG Radioimmun­onkologie

Radioimmunooncology

In my junior research group, we focus on ideas to (i) stimulate tissue regeneration and (ii) improve tumor response rates after radiation therapy or its combination with different types of immunotherapies.

Currently we are focusing on microbiota-host interactions. Using a series of mouse models (e.g., transgenic mice, bone marrow chimeras, treatment with antibiotics, modification of nutrition, supplementation of specific metabolites, recolonization with specific bacteria), we study nutrition-microbiota-host interactions that can be manipulated to try to modulate outcomes after radiation therapy. Recently, we started a new clinical trial (IMMENS) to validate our preclinical observations in human patients and clinically relevant settings. In this trial, we enroll patients that receive radiation therapy of pelvic tumors (e.g., prostate cancer or rectal cancer) and correlate clinical and histopathological endpoints with the composition of the intestinal microbiota and the abundance of specific bacterial metabolites. Our goal is the functional analysis of identified metabolites using experimental models. This study is embedded in the CRC1371 microbiome signatures of the TUM.


Team of my Junior Research Group

  • Sophie Nefzger: Technical Assistant since 07/2020
  • Hannah Felchle (M.Sc.): PhD-Student since 09/2020
  • Caroline Walther: Medical Student since 04/2020
  • Julia Gißibl: Medical Student since 06/2020
  • Laura Lansink Rotgerink: Medical Student since 09/2020
  • Vincent Ruben Timnik: Medical Student since 10/2021
  • Sarah Riedl: Medical Student since 10/2021


Funding

  • 2022 – 2022: German Research Foundation (SFB1371, seed funding)
  • 2022 – 2022: Bayerisches Staatsministerium
  • 2020 – 2023: Deutsche Krebshilfe
  • 2020 – 2023: Else Kröner-Fresenius-Stiftung
  • 2020 – 2021: Bayerisches Staatsministerium
  • 2021 – 2022: Volkswagen Stiftung
  • 2019 – 2022: Clinician Scientist Fellowship des Else Kröner-Forschungs Kollegs "Mikrobielle Trigger als Auslöser von Krankheiten"


Selected Publications

  • Sophie Dobiasch, Severin Kampfer, Katja Steiger, Daniela Schilling, Julius C. Fischer, Thomas E. Schmid, Wilko Weichert, Jan J. Wilkens, Stephanie E. Combs. Histopathological Tumor and Normal Tissue Responses after 3D-Planned Arc Radiotherapy in an Orthotopic Xenograft Mouse Model of Human Pancreatic Cancer. Cancers (Basel). 2021 Nov 12;13(22):5656.

  • Julius C. Fischer, Michael Bscheider, Sascha Göttert, Erik Thiele Orberg, Stephanie E. Combs, Florian Bassermann, Simon Heidegger, Tobias Haas, Hendrik Poeck. Type I interferon signaling before hematopoietic stem cell transplantation lowers donor T cell activation via reduced allogenicity of recipient cells. Scientific Reports, 2019 Oct 18;9(1):14955. doi: 10.1038/s41598-019-51431-2.
  • Simon Heidegger, Alexander Wintges, Florian Stritzke, Sarah Bek, Katja Steiger, Paul-Albert Koenig, Sascha Göttert, Thomas Engleitner, Rupert Öllinger, Tatiana Nedelko, Julius C. Fischer, Vladimir Makarov, Christof Winter, Roland R. Rad, Marcel R.M. van den Brink, Jürgen Ruland, Florian Bassermann, Timothy A. Chan,Tobias Haas, and Hendrik Poeck. RIG-I activation is critical for responsiveness to checkpoint blockade. Science Immunology. 2019 Sep 13;4(39).
  • Nicole Müller*, Julius C. Fischer*, Monica Yabal, Tobias Haas, Hendrik Poeck, and Philipp J. Jost. *Joint first authors. XIAP deficiency in hematopoietic recipient cells drives donor T cell activation and GvHD in mice. Eur J Immunol. 2019 Mar;49(3):504-507. Epub 2019 Jan 3.
  • Julius C. Fischer, Chia-Ching Lin, Simon Heidegger, Alexander Wintges, Martin Schlapschy, Arne Skerra, Tobias Haas, and Hendrik Poeck. Type III interferon dose not contribute to regeneration after radiation- and immune-mediated tissue injury. Int J Radiat Oncol Biol Phys. 2018 Nov 29. pii: S0360-3016(18)34024-0
  • Julius C. Fischer*, Michael Bscheider*, Gabriel Eisenkolb*, Chia-Ching Lin, Alexander Wintges, Vera Otten, Caroline Lindemans, Simon Heidegger, Martina Rudelius, Sébastien Monette, Kori A. Porosnicu Rodriguez, Marco Calafiore, Sophie Liebermann, Chen Liu, Stefan Lienenklaus, Siegfried Weiss, Ulrich Kalinke, Jürgen Ruland, Christian Peschel, Yusuke Shono, Melissa Docampo, Enrico Velardi, Robert Jenq, Alan M. Hanash, Jarrod A. Dudakov, Tobias Haas, Marcel R.M. van den Brink and Hendrik Poeck. RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury. Science Translational Medicine. 2017 Apr 19;9(386).
  • Julius C. Fischer, Alexander Wintges, Tobias Haas and Hendrik Poeck. Assessment of mucosal integrity by quantifying neutrophil granulocyte influx in murine models of acute intestinal injury. Cellular Immunology. 2017 Jun; 316:70-76. Epub 2017 Apr 11.
  • Julius C. Fischer*, Vera Otten*, Maike Kober, Christoph Drees, Marc Rosenbaum, Martina Schmickl, Simon Heidegger, Rudi Beyaert, Geert van Loo, Xian Chang Li, Christian Peschel, Marc Schmidt-Supprian, Tobias Haas, Silvia Spoerl, and Hendrik Poeck. A20 Restrains Thymic Regulatory T Cell Development. Journal of Immunology. 2017 Oct 1;199(7):2356-2365. Epub 2017 Aug 25.
  • Julius C. Fischer*, Vera Otten*, Katja Steiger, Martina Schmickl, Julia Slotta-Huspenina, Rudi Beyaert, Geert van Loo, Christian Peschel, Hendrik Poeck, Tobias Haas, and Silvia Spoerl. A20 deletion in T cells modulates acute graft-versus-host disease in mice. European Journal of Immunology. 2017 Nov;47(11):1982-1988. Epub 2017 Sep 15.
  • Vahl JC, Drees C, Heger K, Heink S, Fischer JC, Nedjic J, Ohkura N, Morikawa H, Poeck H, Schallenberg S, Rieß D, Hein MY, Buch T, Polic B, Schönle A, Zeiser R, Schmitt-Gräff A, Kretschmer K, Klein L, Korn T, Sakaguchi S, Schmidt-Supprian M. Continuous T cell receptor signals maintain a functional regulatory T cell pool. Immunity. 2014 Nov 20;41(5):722-36.

Full publication record: ‪‬Julius C. Fischer‬(link is external) on Google Scholar